Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review

• Published in: Critical reviews in oncology/hematology 2021-09, Vol.165, p.103430-103430, Article 103430
• Main Authors: Lopez-Santillan, Maria, Lopez-Lopez, Elixabet, Alvarez-Gonzalez, Paula, Martinez, Garazi, Arzuaga-Mendez, Javier, Ruiz-Diaz, Irune, Guerra-Merino, Isabel, Gutierrez-Camino, Angela, Martin-Guerrero, Idoia
• Format: Article
• Language: English
• Subjects: Diffuse large B-cell lymphoma; Outcome; Somatic mutation; Therapeutic target
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/j.critrevonc.2021.103430

[Display omitted] •Mutations in CD58 and TP53 seem the most promising predictors of poor outcome.•Combinations of alterations and other prognostic appears as a powerful strategy.•EZH2 inhibitors have been proposed as candidate drug against mutated EZH2 DLBCL.•Ibrutinib could be used for DLBCL with mutations in BCR signaling pathway. Diffuse large B-cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), is a highly heterogeneous and aggressive disease. Regardless of this heterogeneity, all patients receive the same first-line therapy, which fails in 30–40 % of patients, who are either refractory or relapse after remission. With the aim of stratifying patients to improve treatment outcome, different clinical and genetic biomarkers have been studied. The present systematic review aimed to identify somatic mutations that could serve as prognosis biomarkers or as therapeutic target mutations in DLBCL. Regarding their role as prognostic markers, mutations in CD58 and TP53 seem the most promising predictors of poor outcome although the combination of different alterations and other prognostic factors could be a more powerful strategy. On the other hand, different approaches regarding targeted therapy have been proposed. Therefore, mutational analysis could help guide treatment choice in DLBCL yet further studies and clinical trials are needed.